



**Priv. Doz. Dr. med. Siegfried G. Priglinger  
(Abteilungsvorstand)**

- seit 06/2007 Vorstand der Augenabteilung am Allgemeinen Krankenhaus (AKH) Linz
- 08/2007 Ausbildung zum zertifizierten Gesundheitsökonom (BWL-Akademie, Köln)
- 07/2006 Lehrbefähigung und Lehrbefugnis (Habilitation) für das Fach Augenheilkunde
- 06/2005 Oberarzt an der Augenklinik der Universität München
- 02/2005 Facharztprüfung für Augenheilkunde
- 2001 Wissenschaftlicher Assistent an der Augenklinik der Universität München
- 2000 Arzt im Praktikum an der Augenklinik der Universität München
- 1999 Gegenfächer (LKA Salzburg / AKH Linz)
- 1998 Research Fellowship am Schepens Eye Research Institute (Harvard Medical School, Boston)
- 1998 Promotion zum Doktor der gesamten Heilkunde (*summa cum laude*)
- 1991 – 1998 Studium der Humanmedizin an der Medizinischen Fakultät der Universität Wien
- 1989 – 1991 Studium der Biotechnologie an der BOKU Wien
  
- seit 2002 Wissenschaftliche Leitung des MOC (Münchner Ophthalmologisches Curriculum)
- seit 2006 Lehrauftrag an der Ludwig Maximiliansuniversität Universität München
- 2007 Initiation und wissenschaftliche Leitung der LOG (Linzer Ophthalmologische Gespräche)
- seit 2008 Wissenschaftliche Leitung von MAZ – Augen (Mikrochirurgisches Ausbildungs- und Forschungszentrum Linz)

## Wissenschaftliche Publikationen:

1. **Detection of the WT1 transcript by RT-PCR in complete remission has no prognostic relevance in de novo acute myeloid leukemia.** Gaiger A, Schmid D, Heinze G, Linnerth B, Greinix H, Kalhs P, Tislar K, Priglinger S, Laczika K, Mitterbauer M, Novak M, Mitterbauer G, Mannhalter C, Haas OA, Lechner K, Jager U. *Leukemia*. 1998; 12:1886-94. IF: 8,634
2. **Hornhautspende: Einflussfaktoren der Einwilligung;** Krieglstein TR, Neubauer AS, Welge-Lüssen U, Priglinger S, Kampik A, Priemer F. *Ophthalmologie* 2001 Jun;98(6):545-9. IF: 1,133
3. **Elektronische oder papiergebundene Patientenakte -ein Kosten-Nutzenvergleich;** Neubauer AS, Priglinger S, Eht O.. *Ophthalmologie* 2001 Nov;98(11): 1083-1088. IF: 1,133
4. **Kampik A. Vitreoretinal morphology of plasmin-treated human eyes;** Gandorfer A, Priglinger S, Schebitz K, Hoops J, Ulbig M, Ruckhofer J, Grabner G, *Am J Ophthalmol*. 2002;133:156-9. IF: 3,102
5. **Comparison of foveal thickness measured with the retinal thickness analyzer and optical coherence tomography;** Neubauer AS, Priglinger S, Ullrich S, Bechmann M, Thiel MJ, Ulbig MW, Kampik A. *Retina*. 2001;21(6): 596-601. IF: 3,478
6. **Sterile Structural Imaging of Donor Cornea by Optical Coherence Tomography;** Neubauer AS, Priglinger SG, Thiel MJ, May CA, Welge-Lüssen UC. *Cornea*. 2002 Jul;21(5):490-494. IF: 1,853
7. **Consenting to cornea donation: influencing factors;** Krieglstein TR, Welge-Lussen UC, Priglinger S, Kampik A, Priemer F, Neubauer AS. *Graefes Arch Clin Exp Ophthalmol*. 2002 Oct; 240(10):816-821. IF: 1,77
8. **Retinal Pigment Epithelium Is Protected Against Apoptosis by alphaB-Crystallin;** Alge CS, Priglinger SG, Neubauer AS, Kampik A, Zillig M, Bloemendal H, Welge-Lussen U. *Invest Ophthalmol Vis Sci*. 2002 Nov;43(11):3575-82. IF: 3,582
9. **Tissue Transglutaminase as a Modifying Enzyme of the Extracellular Matrix in PVR Membranes;** Priglinger SG, May CA, Neubauer AS, Alge CS, Schonfeld CL, Kampik A, Welge-Lussen U. *Invest Ophthalmol Vis Sci*. 2003 Jan;44(1):355-64. IF: 3,582
10. **Optical coherence tomography for the detection of laser in situ keratomileusis in donor corneas;** Priglinger SG, Neubauer AS, May CA, Alge CS, Wolf AH, Mueller A, Ludwig K, Kampik A, Welge-Luessen U.. *Cornea*. 2003 Jan;22(1):46-50. IF: 1,853
11. **Alkylphosphocholines inhibit proliferation of human retinal pigment epithelial cells;** Eibl KH, Banas B, Schoenfeld CL, May CA, Neubauer AS, Priglinger S, Kampik A, Welge-Lussen U. *Invest Ophthalmol Vis Sci*. 2003 Aug;44(8):3556-61. IF: 3,582
12. **Comparative proteome analysis of native differentiated and cultured dedifferentiated human RPE cells;** Alge CS, Suppmann S, Priglinger SG, Neubauer AS, May CA, Hauck S, Welge-Lussen U, Ueffing M, Kampik A.. *Invest Ophthalmol Vis Sci*. 2003 Aug;44(8):3629-41. IF: 3,582
13. **Tele-screening for diabetic retinopathy with the retinal thickness analyzer;** Neubauer AS, Welge-Lussen UC, Thiel MJ, Alge C, Priglinger SG, Hirneiss C, Ulbig MW, Kampik A.. *Diabetes Care*. 2003 Oct;26(10):2890-7. IF: 7,851
14. **Laser in situ keratomileusis in human corneas; New organ culture model;** May\* CA, Priglinger\* SG, Neubauer AS, Alge CS, Ludwig K, Kampik A, Welge-Lüssen U. *J Cataract Refract Surg*. 2004 Jan;30(1):186-93. (\* contributed equally) IF: 2,508
15. **TGF-beta2-Induced Cell Surface Tissue Transglutaminase Increases Adhesion and Migration of RPE Cells on Fibronectin through the Gelatin-Binding Domain;** Priglinger SG, Alge CS, Neubauer AS, Kristin N, Hirneiss C, Eibl K, Kampik A, Welge-Lussen U. *Invest Ophthalmol Vis Sci*. 2004 Mar;45(3):955-63. IF: 3,582

16. **Screening der diabetischen Retinopathie und Papillentopographie mit dem "Retinal Thickness Analyzer" (RTA);** Neubauer AS, Chryssafis C, Thiel M, Priglinger S, Welge-Lussen U, Kampik A. *Ophthalmologie*. 2005;102:251-8. IF: 1,133
17. **Alkylphosphocholines: A New Therapeutic Option in Glaucoma Filtration Surgery;** Eibl KH, Banas B, Kook D, Ohlmann A, Priglinger S, Kampik A, Welge-Luessen U *Invest Ophthalmol Vis Sci*. 2004; 45:2619-24. IF: 3,582
18. **Functional outcome after trypan-blue-assisted vitrectomy for macular pucker: a prospective, randomized, comparative trial;** Haritoglou C, Eibl K, Schaumberger M, Müller AJ, Priglinger S, Alge C, Kampik A. *Am J Ophthalmol* 2004; 138: 1-5. IF: 3,102
19. **Trypan blue in macular pucker surgery: an evaluation of histology and functional outcome;** Haritoglou C, Gandorfer A, Schaumberger M, Priglinger SG, Mueller AJ, Gass CA, Kampik A. *Retina* 2004; 24: 582-590. IF: 3,478
20. **Histology of the vitreoretinal interface after indocyanine green staining of the ILM with illumination using a halogen and xenon light source;** Haritoglou C, Priglinger SG, Gandorfer A, Welge-Luessen U, Kampik A. *Invest Ophthalmol Vis Sci* 2005; 46: 1468-72. IF: 3,582
21. **Pulsed Electron Avalanche Knife (PEAK-fc) in vitreoretinal surgery;** Priglinger SG, Haritoglou C, Mueller A, Grueterich M, Strauss RW, Alge CS, Gandorfer A, Palanker D, Kampik A.: *Retina*. 2005;25:889-896. IF: 3,478
22. **Pulsed Electron Avalanche Knife (PEAK-fc®) for Dissection of Retinal Tissue;** Priglinger SG, Haritoglou C, Palanker DV, Alge CS, Gandorfer A, Kampik A. *Arch Ophthalmol*. 2005 Oct;123(10):1412-8. IF: 3,242
23. **An evaluation of novel dyes for intraocular surgery;** Haritoglou C, Yu A, Freyer W, Priglinger SG, May CA, Alge C, Eibl K, Welge-Luessen U, Kampik A. *Invest Ophthalmol Vis Sci*. 2005;46:3315-3322. IF: 3,582
24. **Absence of scar formation in a human donor cornea with prior laser in situ keratomileusis (LASIK);** Priglinger SG, May CA, Alge CS, Wolf A, Neubauer AS, Kampik A, Welge-Lüßen U *J Cataract Refract Surg*. 2005;31:1403-1408. IF: 2,508
25. **Mapping of retinal pigment epithelium in exudative age related macular degeneration;** Neubauer AS, Thiel M, Priglinger S, Chryssafis C, Alge C, Welge-Lüßem U, Kampik A. *Graefes Arch Clin Exp Ophthalmol*. 2005;18:1-10; IF: 1,77
26. **Light absorbing properties of indocyanine green (ICG) in solution and on the retinal surface – an ex vivo approach;** Haritoglou C, Freyer W, Priglinger SG, Kampik A. *Graefes Arch Clin Exp Ophthalmol*. 2006; 244:1196-202. IF: 1,77
27. **Galectin-1 influences migration of retinal pigment epithelial cells;** \*Alge CS, \*Priglinger SG, Kook D, Haritoglou C, Welge-Luessen U, Kampik A. *Invest Ophthalmol Vis Sci*. 2006; 47:415-426. (\*contributed equally) IF: 3,582
28. **Inhibition of Human Retinal Pigment Epithelial Cell Attachment, Spreading and Migration by Alkylphosphocholines through Microfilament Modification;** Eibl KH, Kook D, Priglinger S, Haritoglou C, Kampik A, Welge-Luessen U. *Invest Ophthalmol Vis Sci*. 2006; 47:364-370. IF: 3,582
29. **Evaluation of the internal limiting membrane after conventional peeling during macular hole surgery;** Haritoglou C, Schumann R, Reiniger I, Rohleder M, Priglinger SG, Kampik A, Gandorfer A. *Retina* 2006; 26:21-24. IF: 3,478
30. **Immunohistochemical findings after LASIK confirm in vitro LASIK model;** Priglinger SG, May CA, Alge CS, Wolf A, Neubauer AS, Haritoglou C, Kampik A, Welge-Lüßen U.. *Cornea*. 2006; 25:331-335. IF: 1,853
31. **Differential protein profiling of primary versus immortalized human RPE cells identifies expression patterns associated with cell-matrix interactions and cell survival;** Alge CS, Hauck SM, Priglinger SG, Kampik A, Ueffing M. *J Proteome Res*. 2006; 5:862-878. IF: 6,9

32. **Klinische Aspekte bei Frühgeborenen-Retinopathie (ROP). Ergebnisse nach Dioden-Laserkoagulation;** Rudolph G, Buhl M, Pietschmann M, Priglinger S, Boergen K-P, Kampik A. *Klin Monatsbl Augenheilkd.* 2006; 223:528-533. IF: 0,470
33. **Five year follow-up of macular hole surgery with peeling of the internal limiting membrane (ILM): Update of a prospective study;** Haritoglou C, Reiniger I, Schaumberger M, Gass C, Priglinger SG, Kampik A. *Retina* 2006; 26:618-622. IF: 3,478
34. **Tissue Transglutaminase modifies Extracellular Matrix after Glaucoma Filtering Surgery;** Priglinger SG, Alge CS, Kook D, Thiel M, Schumann R, Kampik A, Welge-Luessen U. *Invest Ophthalmol Vis Sci.* 2006;47:3835-45. IF: 3,582
35. **Pulsed Electron Avalanche Knife (PEAK-fc): New Technology for capsulotomy in congenital and mature cataract;** Priglinger SG, Haritoglou C, Palanker D, Kook D, Grueterich M, Mueller A, Alge CS, Kampik A. *J Cataract Refract Surg.* 2006;32:1085-1088. IF: 2,508
36. **Short time in vivo evaluation of novel vital dyes for intraocular surgery;** Haritoglou C, Tadayoni R, May CA, Gass C, Freyer W, Priglinger SG, Kampik A. *Retina* 2006; 26:673-678. IF: 3,478
37. **Topography of Diabetic Macular Edema compared to Fluorescein Angiography;** Neubauer AS, Chryssafis C, Priglinger SG, Haritoglou C, Thiel M, Welge-Lüssen U, Kampik A, Ulbig M. *Acta Ophthalmol Scand.* 2007;85:32-9. IF: 2,138
38. **Keratinocyte transglutaminase in proliferative vitreoretinopathy;** Priglinger SG, Alge CS, Kreuzer TC, Neubauer AS, Haritoglou C, Kampik A, Welge-Luessen U. *Invest Ophthalmol Vis Sci.* 2006; 47:4990-4997. IF: 3,582
39. **Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema;** Haritoglou C, Kook D, Neubauer AS, Wolf A, Priglinger S, Strauss R, Gandorfer A, Ulbig M, Kampik A.. *Retina.* 2006; 26:999-1005. IF: 3,478
40. **Visual quality of life after Macular Hole Surgery: Outcome and predictive factors;** Hirneiss C, Neubauer AS, Gass CA, Reiniger IW, Priglinger SG, Kampik A, Haritoglou C. *Br J Ophthalmol.* 2007;91:481-4. IF: 2,859
41. **Hypoxia/Reoxygenation and TGF-beta Increase alphaB-Crystallin Expression in Human Optic Nerve Head Astrocytes;** Yu AL, Fuchshofer R, Birke M, Priglinger SG, Eibl KH, Kampik A, Bloemendal H, Welge-Lussen U.. *Exp Eye Res.* 2007;84:694-706. IF: 2,579
42. **Long-term functional outcome of macular hole surgery correlated to Optical Coherence Tomography (OCT) measurements;** Haritoglou C, Neubauer A, Reiniger IW, Priglinger SG, Gass CA, Kampik A.. *Clin Experiment Ophthalmol.* 2007;35:208-13. IF: 1,347
43. **Pulsed Electron Avalanche Knife (PEAK-fc): New Technology for Cataract Surgery;** Priglinger SG, Palanker D, Alge CS, Haritoglou H, Grueterich M, Kampik A.. *Br J Ophthalmol.* *Br J Ophthalmol.* 2007; 91:949-54. IF: 2,859
44. **Vitreoretinal surgery using Bromphenol blue as a vital stain: Evaluation of staining characteristics in humans;** Haritoglou C, Schumann R, Strauss R, Priglinger S, Neubauer AS, Kampik A.. *Br J Ophthalmol.* 2007; 91:1125-8. IF: 2,859
45. **Eccentric lamellar keratolimbal grafts harvested with a manually guided microkeratome. Technical report;** Grueterich M, Kenyon KR, Priglinger S, Welge-Luessen U, Lackerbauer C, Kampik A. *Ophthalmic Res.* 2007; 39:179-83. IF: 1,317
46. **Nonmydriatic screening for diabetic retinopathy by ultra-widefield scanning laser ophthalmoscopy (Optomap);** Neubauer AS, Kernt M, Haritoglou C, Priglinger SG, Kampik A, Ulbig MW.. *Graefes Arch Clin Exp Ophthalmol.* 2008; 246:229-35. IF: 1,498
47. **Retinal pigment epithelial tears after intravitreal injection of bevacizumab for AMD: Frequency and progress;** Kook D, Wolf A, Neubauer AS, Haritoglou C, Priglinger SG, Kampik A, Ulbig MW. *Ophthalmologie.* 2008;105:158-64. IF: 1,133

48. **Intravitreal Bevacizumab for Central Retinal Vein Occlusion - Six Month Results of a Prospective Trial;** Priglinger SG, Wolf AH, Kreutzer TC, Kook D, Hofer A, Strauss RW, Alge CS, Kunze C, Haritoglou C, Kampik A.. *Retina*. 2007; 27:1004-12. IF: 3,478
49. **Indications and Clinical Outcome of Capsular Tension Ring (CTR) Implantation: A Review of 9528 Cataract Surgeries;** Tribus C, Alge CS, Haritoglou C, Kampik A, Mueller A. Priglinger SG.. *Clinical Ophthalmology*. 2007;1(1) 65-69. IF: 1,347
50. **Image quality characteristics of a novel colour scanning digital ophthalmoscope (SDO) compared with fundus photography.** Strauss RW, Kriegelstein TR, Priglinger SG, Reis W, Ulbig MW, Kampik A, Neubauer AS. *Ophthalmic Physiol Opt*. 2007; 27:611-8. IF: 1,00
51. **Bevacizumab and retinal ischemia.**Neubauer AS, Kook D, Haritoglou C, Priglinger SG, Kampik A, Ulbig MW, Ceklic L.; *Ophthalmology*. 2007; 114:2096. IF: 5,296
52. **Bromphenol blue staining in eyes with mature cataract.** Haritoglou C, Priglinger SG, Strauss R, Gandorfer A, Kampik A. *J Cataract Refract Surg*. 2007; 33:2155-7. IF: 2,508
53. **Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion.** Kreutzer TC, Alge CS, Wolf AH, Kook D, Burger J, Strauss R, Kunze C, Haritoglou C, Kampik A, Priglinger SG. *Br J Ophthalmol*. 2008; 92:351-5. IF: 2,859
54. **Delineation of the vitreous and posterior hyaloid using bromophenol blue.** Haritoglou C, Strauss R, Priglinger SG, Kreutzer T, Kampik A. *Retina*. 2008; 28:333-9. IF: 3,478
55. **Retinal vessel analysis reproducibility in assessing cardiovascular disease.** Neubauer AS, Lüdtke M, Haritoglou C, Priglinger S, Kampik A. *Optom Vis Sci*. 2008; 85:247-54. IF: 1.579
56. **The protective effect of quercetin against oxidative stress in the human RPE in vitro.** Kook D, Wolf AH, Yu AL, Neubauer AS, Priglinger SG, Kampik A, Welge-Lüssen UC. *Invest Ophthalmol Vis Sci*. 2008; 49:1712-20. IF: 3,582
57. **Capsular tension ring-based in vitro capsule opacification model.** Burger J, Kreutzer T, Alge CS, Strauss RW, Eibl K, Haritoglou C, Neubauer AS, Kampik A, Priglinger SG. *J Cataract Refract Surg*. 2008; 34:1167-72. IF: 2,508
58. **An in vivo evaluation of Brilliant Blue G in animals and humans.** Remy M, Thaler S, Schumann RG, May CA, Fiedorowicz M, Schuettauf F, Grüterich M, Priglinger SG, Nentwich MM, Kampik A, Haritoglou C. *Br J Ophthalmol*. 2008; 92:1142-7. IF: 2.859
59. **Vital dyes for macular surgery: a comparative electron microscopy study of the internal limiting membrane.** Schumann RG, Gandorfer A, Priglinger SG, Kampik A, Haritoglou C. *Retina*. 2009; 29:669-76. IF: 3,478
60. **Macula-off retinal detachment--a matter of time?** Henrich PB, Priglinger S, Klaessen D, Kono-Kono JO, Maier M, Schötzau A, Meyer P, Josifova T, Schneider U, Flammer J, Haritoglou C. *Klin Monatsbl Augenheilkd*. 2009; 226:289-93. IF: 0,470
61. **Alkylphosphocholines as a potential pharmacologic prophylaxis for posterior capsule opacification.** Eibl KH, Liegl R, Kernt M, Priglinger S, Kampik A. *J Cataract Refract Surg*. 2009; 35:900-5. IF: 2.508
62. **Optimizing the deswelling process of organ-cultured corneas.** Wolf AH, Welge-Lüssen UC, Priglinger S, Kook D, Grueterich M, Hartmann K, Kampik A, Neubauer AS. *Cornea*. 2009; 28:524-9. IF: 1.853
63. **Anatomical and functional outcome in brilliant blue G assisted chromovitrectomy.** Henrich PB, Haritoglou C, Meyer P, Ferreira PR, Schötzau A, Katamay R, Josifova T, Schneider U, Flammer J, Priglinger S. *Acta Ophthalmol*. 2009 Apr 23. IF: 2.138
64. **Oxidative Stress-mediated Induction of MMP-1 and MMP-3 in human RPE cells;** Alge-Priglinger CS, Kreutzer T, Obholzer Katja, Wolf A, Mempel M, Kernt M, Kampik A, Priglinger SG. *Invest Ophthalmol Vis Sci*. 2009 Jun 10 (Epub ahead of print). IF: 3,582